Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Inclusion Criteria: * Histologic diagnosis of ovarian, fallopian or primary peritoneal cancer (excluding borderline histologies). Preliminary pathology results based on frozen section findings are acceptable. * The interval between pelvic or abdominal surgery and first dose of study treatment must be no more than 10 days. * Age ≥ 18 years. * ECOG performance status ≤2 (see Appendix A) * Life expectancy of greater than 6 months * Participants must have normal organ and marrow function as defined below: * Platelets ≥ 100,000/mcL * Total Bilirubin \<1.5 mg/dL (or direct bilirubin \<1.0 mg/dL) * AST(SGOT) ≤ 1.5 × institutional upper limit of normal * ALT(SGPT) ≤ 1.5 × institutional upper limit of normal * Creatinine \< 1.5 mg/dL OR * Estimated creatinine clearance ≥60 mL/min/1.73 m2 * The effects of rosuvastatin on the developing human fetus are unknown. For this reason and because statins used in this trial are thought to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Participants who are receiving any other investiga…